An interventional study of Multidisciplinary inhaler optimization intervention in Pulmonary Disease, Chronic Obstructive (COPD) and Asthma (Diagnosis), sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Not applicable, Interventional, and Health services research
Among 87 studies in Lung Diseases with a site in Spain — 25 open to participants now, 35 under way, 14 of them phase 3. Lung Diseases · Spain.
Among the 87 studies in Lung Diseases with a site in Spain, this one is the 58th largest by planned enrollment of the 76 interventional ones that give a count, is the only one that started in 2027, is one of 13 with no phase, reaches primary completion later than 27 of the 34 other live ones, and was the 87th registered.
1,158 studies on the registry are indexed under Lung Diseases; 182 are open to participants now.
Browse Lung Diseases studies →25 of the 87 studies in Lung Diseases with a site in Spain are open now. Recruiting first, the newest first:
Pfizer · Sites in Spain, United States, Australia and 8 more countries
Ages 18+
Grifols Therapeutics LLC · Sites in Spain, United States, Denmark and 6 more countries
Ages 18–80
MediLink Therapeutics (Suzhou) Co., Ltd. · Sites in Spain, United States, Belgium and 6 more countries
Ages 18+
AIRNA Corporation · Sites in Spain, Australia, Georgia and 6 more countries
Ages 18–74
Fundación GECP · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 140 Lung Diseases studies recruiting now, 76 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 16 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 26 · Phase 3 30 · Phase 4 6
First in 2004; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 70 across 663 interventional studies indexed under Lung Diseases.
Median enrollment 238 across the 76 interventional studies, 105 across the 10 observational. Of the 43 that completed or were terminated, 19 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 87 have an industry lead sponsor. The 10 most frequent:
Consorci Sanitari de l'Alt Penedès i Garraf is the lead sponsor of 43 studies on the registry; 20 are open to participants now.
Consorci Sanitari de l'Alt Penedès i Garraf has 1 study filed under Lung Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Lung Diseases with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT05973773Phase 3Taiho Oncology, Inc.REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | 2027-05-27 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 87 studies in Lung Diseases with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if a multidisciplinary review of inhaler treatment can increase the use of inhalers with a lower environmental impact in adults admitted to intermediate care units who use inhalers. The main questions it aims to answer are:
Participants will:
The health sector generates about 5% of global greenhouse gas emissions, and pressurized metered-dose inhalers (pMDIs), which contain propellants with a high global warming potential, are a relevant part of this footprint. Dry powder inhalers (DPIs) and soft mist inhalers (SMIs) are more sustainable alternatives. In 2025, the Spanish Ministry of Health issued recommendations on sustainable inhaler prescribing that include reviewing the indication, optimizing inhaler technique and adherence, and switching to lower-impact devices when appropriate.
This quasi-experimental study with two arms and stepped implementation over three periods will be conducted in the intermediate care units of Hospital Sant Antoni Abat. Allocation is determined by the treating geriatrician: patients of two of the four geriatricians form group 1 and those of the other two form group 2. In period 1 (3 months, retrospective data), neither group receives the intervention; in period 2 (about 6 months), only group 2 receives it; in period 3 (about 3 months), both groups receive it.
The intervention, delivered within one week of inclusion, consists of: (1) a physician review of the inhaled therapy prescription in the electronic prescription system, with changes if needed, also considering environmental criteria; (2) assessment of adherence with the Test of Adherence to Inhalers (TAI), classifying adherence (good, intermediate, poor) and type of non-adherence (erratic, deliberate, unwitting); (3) assessment of inhaler technique with device-specific checklists (GINA, UK Inhaler Group); and (4) individualized education and, if the device is not suitable or rescue inhaler use is excessive, a switch to a lower-impact inhaler.
The primary analysis will compare, in period 2, the percentage of prescriptions of each inhaler type at admission and at discharge. Assuming a switch from pMDI to DPI in 5% of the control group and 20% of the intervention group, 50 patients per group are needed for period 2 (two-sided alpha 0.05, power above 80%), with an expected 10% loss to follow-up. CO2 emissions will be estimated from the Spanish database on the environmental impact of inhalers. Analysts will be blinded to the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients of two geriatricians; usual care in periods 1 and 2, multidisciplinary inhaler intervention in period 3
Other: Multidisciplinary inhaler optimization intervention
Patients of the other two geriatricians; usual care in period 1, multidisciplinary inhaler intervention in periods 2 and 3
Other: Multidisciplinary inhaler optimization intervention
Within one week of admision, a physician reviews the inhaled therapy prescription (indication, duration) and changes it if needed, also considering environmental impact. A healthcare professional assesses adherence with the Test of Adherence to Inhalers (TAI) and inhaler technique with device-specific checklists (GINA, UK Inhaler Group), and provides individualized education. If the device is not suitable or rescue inhaler use is excessive, the physician considers switching to a lower-impact inhaler (dry powder or soft mist inhaler).
Percentage of prescriptions of each inhaler type
Percentage of prescriptions of pressurized metered-dose inhalers (pMDI), dry powder inhalers (DPI), and soft mist inhalers (SMI) in the electronic prescription system, compared between admission and discharge in the intervention and control groups during period 2.
Time frame: At admission and at discharge from the intermediate care unit, maximal up to 1 year from admission
Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).
Supporting information: Study protocol
Time frame: After publication of main results of the study.
Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
Of 184 non-industry interventional studies with no phase under Lung Diseases, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 23 months is close to that.
Counting every sponsor, half of 207 studies reached it within 22 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorci Sanitari de l'Alt Penedès i Garraf